Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.
Immutep Limited (IMMP) is a clinical-stage biotechnology leader pioneering LAG-3 immunotherapies for cancer and autoimmune diseases. This dedicated news hub provides investors and industry professionals with timely updates on the company's clinical advancements, regulatory milestones, and strategic initiatives.
Key resources include: Press releases detailing trial results for therapies like IMP321 and IMP701, financial disclosures from global exchanges, partnership announcements with major pharmaceutical collaborators, and scientific presentations demonstrating LAG-3 innovation. All content is sourced directly from company filings and verified channels.
Bookmark this page for streamlined access to Immutep's latest developments in immuno-oncology research, including updates from ongoing clinical programs and analyses of emerging therapeutic strategies. Check regularly for real-time insights into one of biotech's most active immunotherapy pipelines.
Immutep has reported positive initial clinical data from the Phase II EFTISARC-NEO trial, combining efti with radiotherapy and pembrolizumab in soft tissue sarcoma patients. The trial showed very good pathologic responses rarely seen with standard therapies, with 67% of patients having near-complete responses. This novel triple combination was well tolerated, with no new safety concerns.
Immutep provides an update on its product candidates development, including positive clinical data in breast cancer and head and neck squamous cell carcinoma patients, progress in various phase II and III trials, appointment of a new director, and financial summary. The Company remains well-funded with a cash balance of approximately $95.4 million as of March 31, 2024.
FAQ
What is the current stock price of Immutep (IMMP)?
What is the market cap of Immutep (IMMP)?
